Announcements
-
18-Jul-2017
The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company met today to approve financial results for the quarter ended June 30, 2017.
+
-
21-Jun-2017
Jubilant Life Sciences, an integrated global pharmaceutical and life sciences company, today announced a strategic partnership with Barentz International, an international leader in the distribution of high-quality ingredients. The two companies, have signed a commercial agreement to work together within the food & nutrition market in India and its neighbouring countries. The collaboration aims at delivering solutions in food nutrition and fortification.
+
-
25-May-2017
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced a price increase of up to 15% for its Vitamin B3 (Niacin & Niacinamide) with immediate effect, for non-contract customers and wherever existing contracts permit. This is further to the price increase of up to 15% announced in December 2016.
+
-
23-May-2017
The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company met today to approve financial results for the quarter and year ended March 31, 2017.
+
-
17-May-2017
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Amlodipine and Olmesartan Medoxomil Tablets 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg, the generic version of Azor® of Daiichi Sankyo, which is used for the treatment of hypertension.
+
-
05-May-2017
Jubilant Life Sciences Limited, an integrated global Pharmaceuticals and Life Sciences Company, today announced that Jubilant Pharma Limited (“JPL”), a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has signed an Asset Purchase Agreement with Triad Isotopes Inc. and its parent, Isotope Holdings, Inc. (“Triad”) to acquire substantially all of the assets which comprise the radiopharmacy business of Triad. The closing of the transaction is subject to customary closing conditions, including contract, regulatory and other approvals.
+
-
25-Apr-2017
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg, and 40 mg, the generic version of Benicar® of Daiichi Sankyo, which is used for the treatment of hypertension.
+
-
06-Apr-2017
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, the generic version of Celebrex® of GD Searle, which is used for the treatment of Osteoarthritis and Rheumatoid Arthritis.
+
-
28-Mar-2017
The Schwab Foundation for Social Entrepreneurship, a sister organization of the World Economic Forum, in partnership with the Jubilant Bhartia Foundation announces opening of entries for the annual competition –Social Entrepreneur of the Year (SEOY) India Award 2017
+
-
27-Feb-2017
Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Itraconazole Capsules, 100 mg, the generic version of Sporanox® of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.
+